MENU
CLYM
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Climb Bio (CLYM) Ownership - Who owns Climb Bio?

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases... Show more

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
161.28M
P/E Ratio
N/A
Total Cash
84.7M
Projected Growth
N/A
Total Debt
639K
Revenue
N/A
Risk (Beta)
-1.63
Dividend Yield
N/A
Total Cash/Share
1.25
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price

Fundamentals

CLYM
Capitalization
161M
P/E Ratio
N/A
Risk (Beta)
-1.63
Dividend Yield
N/A
Total Cash
84.7M
Total Cash/Share
1.25
Total Debt
639K
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
186M
P/B Ratio
0.87
Cash Flow
N/A
Earnings
-0.02
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
7K
Current Ratio
14.08
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-4.68M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-22.35
Shares Held By Institutions
67.3M
Shares Outstanding - Current
67.8M
Total Liabilities
6.62M
Total Volume MTD
N/A
Value
1
Gain YTD
32.222
View a ticker or compare two or three
CLYM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. CLYM showed earnings on August 12, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details